Odyssey Therapeutics IPO: revenue, losses and offering terms from its S-1
Odyssey Therapeutics priced its IPO at $18 a share on 8 May 2026 and raised $279 million. Its shares trade on Nasdaq as ODTX. Revenue was $3.0 million in 2025, down 33% from 2024, with a net loss of $149 million.
Headlines
- Revenue, 2025
- $3M
- Down 33% on the year before
- Net loss, 2025
- $149M
- IPO price
- $18
- $279M raised
Odyssey Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Capital Market
- Ticker
- ODTX
- IPO price
- $18
- Shares offered
- 15,500,000
- Raised
- $279M
- Registered
- $274M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, TD Cowen, Cantor, Wedbush, PacGrow and Oppenheimer & Co.
- First filed
- 17 Jan 2025
Odyssey Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $4M | - | -$129M |
| 2025 | $3M | -$157M | -$149M |
Odyssey Therapeutics share structure and company facts
- Employees
- 100
- Headquarters
- Boston, Massachusetts
Odyssey Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 8 May 2026
- First close
- $16.42
- -9% on the IPO price
- Latest close
- $19.30
- +7% on the IPO price
Odyssey Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Odyssey Therapeutics' newest prospectus (424B4 filed 8 May 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.